China NT Pharma Group Co Ltd (1011):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:China NT Pharma Group Co Ltd (1011) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9945
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:香港
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
China NT Pharma Group Co Ltd (NT Pharma) is a technology-based pharmaceutical company, which researches, develops, manufactures, and distributes branded and generic pharmaceuticals. The company also promotes and distributes drugs manufactured by third parties. It develops drugs for indications such as cancer; central nervous system disorders; orthopedics; hepatopathy and respiratory disorders. NT Pharma’s branded products include Libod and Xi Di Ke for the treatment of various cancers; Miacalcic for bone pain; Shusi, an antipsychotic drug; Zhuo’ao, a respiratory drug, and Songzhi Wan, a traditional Chinese medicine for the treatment of Hepatitis C. The company operates three production bases for chemical drugs, traditional Chinese medicine and bio-chemical drugs through its subsidiaries, Suzhou First, Jiangsu Biopharma and Changsha Pharma. It operates a research and development facility in Beijing. NT Pharma is headquartered in Wanchai, Hong Kong.

China NT Pharma Group Co Ltd (1011) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
China NT Pharma Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 11
Partnerships 12
China NT Pharma To Form Joint Venture With Sinopharm 12
Licensing Agreements 13
Pfenex Enters into Licensing Agreement with China NT Pharma Group 13
Equity Offering 14
China NT Pharma to Raise USD43 Million in Private Placement of Shares 14
China NT Pharma to Raise USD19 Million in Private Placement of Shares 15
Debt Offering 16
China NT Pharma Completes Private Placement Of Bonds Due 2016 For US$48 Million 16
Acquisition 17
China NT Pharma Group to Acquire 100% stake in Hunan Kexing Jimeng Pharmaceutical for USD15.27 Million 17
China NT Pharma Completes Acquisition Of Remaining 20% Stake In Suzhou First Pharma For US$9.5 Million 19
China NT Pharma Group Co Ltd – Key Competitors 20
China NT Pharma Group Co Ltd – Key Employees 21
China NT Pharma Group Co Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Mar 26, 2018: China NT Pharma: Annual Results Announcement For the Year Ended 31 December 2017 23
Aug 21, 2017: China NT Pharma: Interim Results Announcement for the Six Months Ended 30 June 2017 24
Mar 21, 2017: China NT Pharma Group Company: Annual Results Announcement For The Year Ended 31 December 2016 27
Corporate Communications 28
Jul 31, 2017: China NT Pharma: Appointment And Resignation Of Non-Executive Director 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
China NT Pharma Group Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
China NT Pharma Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 11
China NT Pharma To Form Joint Venture With Sinopharm 12
Pfenex Enters into Licensing Agreement with China NT Pharma Group 13
China NT Pharma to Raise USD43 Million in Private Placement of Shares 14
China NT Pharma to Raise USD19 Million in Private Placement of Shares 15
China NT Pharma Completes Private Placement Of Bonds Due 2016 For US$48 Million 16
China NT Pharma Group to Acquire 100% stake in Hunan Kexing Jimeng Pharmaceutical for USD15.27 Million 17
China NT Pharma Completes Acquisition Of Remaining 20% Stake In Suzhou First Pharma For US$9.5 Million 19
China NT Pharma Group Co Ltd, Key Competitors 20
China NT Pharma Group Co Ltd, Key Employees 21
China NT Pharma Group Co Ltd, Subsidiaries 22

List of Figures
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
China NT Pharma Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[China NT Pharma Group Co Ltd (1011):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Toyota Industries Corporation:企業の戦略・SWOT・財務分析
    Toyota Industries Corporation - Strategy, SWOT and Corporate Finance Report Summary Toyota Industries Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Oasmia Pharmaceutical AB (OASM):企業の財務・戦略的SWOT分析
    Summary Oasmia Pharmaceutical AB (Oasmia Pharmaceutical) is a pharmaceutical company that develops, manufactures, markets and sells drugs for human and veterinary oncology. The company’s pipeline for human health includes apealea (paclical), currently at registration and approval stage, for treating …
  • Nordic American Tankers Ltd (NAT):石油・ガス:M&Aディール及び事業提携情報
    Summary Nordic American Tankers Limited (NAT) is a tanker company. It transports crude oil through its fleet of double-hull Suezmax tankers. The company operates its vessels on bareboat charters, time charters, and spot charters. NAT’s tankers are capable of carrying high volumes of oil and able to …
  • Lumenis Ltd:企業の戦略的SWOT分析
    Lumenis Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Biotronik SE & Co KG:企業の戦略的SWOT分析
    Biotronik SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • UNITIKA LTD.:企業の戦略・SWOT・財務分析
    UNITIKA LTD. - Strategy, SWOT and Corporate Finance Report Summary UNITIKA LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Otto Bock HealthCare GmbH-医療機器分野:企業M&A・提携分析
    Summary Otto Bock HealthCare GmbH (Otto Bock), a group company of Otto Bock Holding GmbH & Co. KG, is a medical device company that manufactures and distributes prosthetic and orthotic devices. It also offers mobility and seating solutions for the physically disabled adults and children. The product …
  • Finastra Group Holdings Limited:企業の戦略・SWOT・財務情報
    Finastra Group Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Finastra Group Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • ALSTOM SA:企業の戦略・SWOT・財務分析
    ALSTOM SA - Strategy, SWOT and Corporate Finance Report Summary ALSTOM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • KKR Financial Holdings LLC:企業の戦略・SWOT・財務情報
    KKR Financial Holdings LLC - Strategy, SWOT and Corporate Finance Report Summary KKR Financial Holdings LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Genfit SA (GNFT)-医療機器分野:企業M&A・提携分析
    Summary Genfit SA (Genfit) is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s product pipeline comprise GFT505, TGFTX1, TGFTX3, TGFTX4, TGFTX5 and SAN/GFT-2. Its TGFTX1 can be …
  • IBIDEN CO., LTD.:戦略・SWOT・企業財務分析
    IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report Summary IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Yasuhara Chemical Co Ltd (4957):企業の財務・戦略的SWOT分析
    Yasuhara Chemical Co Ltd (4957) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Matthews International Corp (MATW):企業の財務・戦略的SWOT分析
    Matthews International Corp (MATW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Cohort Plc:企業の戦略・SWOT・財務分析
    Cohort Plc - Strategy, SWOT and Corporate Finance Report Summary Cohort Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Wilson Vale:企業の戦略・SWOT・財務情報
    Wilson Vale - Strategy, SWOT and Corporate Finance Report Summary Wilson Vale - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • AF Gruppen ASA (AFG):企業の財務・戦略的SWOT分析
    AF Gruppen ASA (AFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • The Miyazaki Taiyo Bank, Ltd.:企業の戦略・SWOT・財務情報
    The Miyazaki Taiyo Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Miyazaki Taiyo Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Providence Resources plc (PZQA):企業の財務・戦略的SWOT分析
    Summary Providence Resources Plc (Providence Resource) is an upstream oil and gas exploration and development company that explores and develops hydrocarbon assets. The company's areas of operations include Northern Porcupine basin, Southern Porcupine basin, Goban Spur basin, Saint George's basin an …
  • Zurich UK:企業の戦略・SWOT・財務情報
    Zurich UK - Strategy, SWOT and Corporate Finance Report Summary Zurich UK - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆